SELLAS Life Sciences (SLS) Other financing activities (2010 - 2026)
SELLAS Life Sciences' (SLS) quarterly Other financing activities came in at $66000.0 in Q1 2026, up 37.5% year-on-year from $48000.0 in Q1 2025, and up 100.3% on a QoQ basis from -$21.9 million in Q4 2025.
SELLAS Life Sciences (SLS) Other financing activities (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 13 years of Other financing activities data on file, last reported at $66000.0 in Q1 2026.
- On a quarterly basis, Other financing activities rose 37.5% year-over-year to $66000.0 in Q1 2026; TTM through Mar 2026 was $130000.0, a 76.74% decrease from a year earlier, with the FY2025 full-year figure at $112000.0, down 80.0% from the prior year.
- Other financing activities for Q1 2026 stood at $66000.0, up from -$21.9 million in the prior quarter.
- Over the last five years, Other financing activities for SLS reached as high as $22.0 million in Q3 2025 and fell as low as -$21.9 million in Q4 2025.
- Historically, Other financing activities has averaged $74250.0 across 5 years, with a median of $47500.0 in 2022.
- On a YoY basis, Other financing activities climbed as much as 4226.57% in 2025 and fell as far as 2191600.0% in 2025.
- Year by year, Other financing activities stood at $38000.0 in 2022, then sank by 63.16% to $14000.0 in 2023, then sank by 92.86% to $1000.0 in 2024, then sank by 2191600.0% to -$21.9 million in 2025, then soared by 100.3% to $66000.0 in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were $66000.0 in Q1 2026, -$21.9 million in Q4 2025, and $22.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66,000.00 |
| Mar 31, 2026 | 66,000.00 |
| Dec 31, 2025 | -21.92 Mn |
| Dec 31, 2025 | -21.92 Mn |
| Sep 30, 2025 | 21.98 Mn |
| Sep 30, 2025 | 21.98 Mn |
| Mar 31, 2025 | 48,000.00 |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 508,000.00 |
| Sep 30, 2024 | 508,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 54,000.00 |
| Sep 30, 2023 | 54,000.00 |